Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 5, 2006, Pages 461-467

  Burnett, John R ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; CHOLESTEROL; COLESTYRAMINE; EZETIMIBE; FATTY ACID BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISIS 147764; ISIS 281625; ISIS 301012; ISIS 301027; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; HUMAN; HYPERCHOLESTEROLEMIA; INHIBITION KINETICS; INJECTION SITE REACTION; LIPID DIET; LIVER DYSFUNCTION; LIVER TOXICITY; MONKEY; NONHUMAN; PATENT; REVIEW; TREATMENT OUTCOME;

APOLIPOPROTEIN B-100; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; HYPERCHOLESTEROLEMIA; OLIGONUCLEOTIDES, ANTISENSE;

EID: 33750006043     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. 514094 Inhibition of human apoB-100 in transgenic mice. Graham MJ, Lemonidis KM, Whipple C, Petinos N, Crooke RM CIRCULATION 2003 108 17 Abs 836
2. 572846 Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M et al NATURE 2004 432 7014 173-178
3. 606494 Isis's anticholesterol drug has rapid and long-lasting effects in phase I. Isis Pharmaceuticals Inc PRESS RELEASE 2005 June 09
4. 608132 Hypolipidemic effects of a novel inhibitor of human apoB-100 in humans. Bradley JD, Crooke R, Kjems LL, Graham M, Leong R, Yu R, Paul D, Wedel M DIABETES 2005 54 6 Suppl 1 Abs 977-P
5. 623904 Isis begins phase II trials of ISIS-301012 for high cholesterol. Isis Pharmaceuticals Inc PRESS RELEASE 2005 September 20
6. 632784 Isis begins phase II study of antilipemic drug. Isis Pharmaceuticals Inc PRESS RELEASE 2005 November 07
7. 648867 Positive phase I results for Isis's oral hypercholesterolemia drug. Isis Pharmaceuticals Inc PRESS RELEASE 2006 February 07
8. 649415 Isis Pharmaceuticals presents additional clinical data showing that ISIS 301012 significantly reduces triglycerides. Isis Pharmaceuticals Inc PRESS RELEASE 2006 February 09
9. 655117 Isis's ISIS-301012 does not interact with lipid-lowering drugs. Isis Pharmaceuticals Inc PRESS RELEASE 2006 March 13
10. 657921 RNAi-mediated gene silencing in non-human primates. Zimmermann TS, Lee ACH, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD et al NATURE 2006 441 7089 111-114
11. 661135 An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ J LIPID RES 2005 46 5 872-884
12. 661136 Antisense inhibitor provides new treatment approach for hypercholesterolaemia. Senior K DRUG DISC TODAY 2002 7 16 840-841
13. 661137 Small, dense, LDL particle concentration is significantly reduced after treatment with an antisense inhibitor of ApoB in healthy volunteers. Bradley JA, Crooke R, Graham M, Wedel M CIRCULATION 2005 112 Abs 727
14. 661138 Inhibition of apoB-100 as a therapeutic strategy for the treatment of hyperlipidemias. Graham MJ, Marturano BM, Lemonidis KM, Crooke RM CIRCULATION 2002 106 Abs 548
15. 664411 Isis's antisense drug lowers cholesterol in phase II trial. Isis Pharmaceuticals Inc PRESS RELEASE 2006 April 27
16. 669766 NCT00280995 - Dose-escalating safety study of ISIS 301012 in homozygous familial hypercholesterolemia subjects on lipid lowering therapy. National Institutes of Health INTERNET SITE 2006 January 31
17. 669794 NCT00216463 - Safety and tolerability of varying load and dose of ISIS 301012 in people with elevated LDL-cholesterol levels. National Institutes of Health INTERNET SITE 2006 February 28
18. 670650 ISIS-301012 gets US Orphan status for hypercholesterolemia. Isis Pharmaceuticals Inc PRESS RELEASE 2008 June 01
19. 663468 Apolipoprotein B metabolism: Tracer kinetics, models, and metabolic studies. Burnett JR, Barrett PH CRIT REV CLIN LAB SCI 2002 39 2 89-137
20. 673470 The assembly and secretion of apolipoprotein B-containing lipoproteins. Olofsson SO, Asp L, Boren J CURR OPIN LIPIDOL 1999 10 4 341-346
21. 673487 Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism. Hooper AJ, van Bockxmeer FM, Burnett JR CRIT REV CLIN LAB SCI 2005 42 5-6 515-545
22. 673490 Sharp D, Blinderman L, Combs KA, Kienzie B, Ricci B, Wager-Smith K, Gil CM, Turck CW, Bouma ME, Rader DJ et al Cloning and gene defects in microsomal triglyceride transfer protein associated with abetallpoproteinaemia. NATURE 1993 366 6441 65-69
23. 673494 Current biology of MTP: Implications for selective inhibition. Shoulders CC, Shelness GS CURR TOP MED CHEM 2005 5 3 283-300
24. 673550 Lipid disorders and mutations In the APOB gene. Whitfield AJ, Barrett PH, van Bockxmeer FM, Burnett JR CLIN CHEM 2004 50 10 1725-1732
25. 676706 ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI Lenfant C J AM COLL CARDIOL 2002 40 3 567-572
26. 677299 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ CIRCULATION 2004 110 2 227-239
27. 677304 Rationale for combination therapy with statin drugs in the treatment of dysllpidemia. Ansell BJ CURR ATHEROSCLEROSIS REP 2005 7 1 29-33
28. 684436 The complete cDNA and amino acid sequence of human apolipoprotein B-100. Chen SH, Yang CY, Chen PF, Selzer D, Tanimura M, Li WH, Gotto AM Jr, Chan L J BIOL CHEM 1986 261 28 12918-12921
29. 684440 A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Powell LM, Wallis SC, Pease RJ, Edwards YH, Knott TJ, Scott J CELL 1987 50 6 831-840
30. 684441 The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. Navaratnam N, Morrison JR, Bhattacharya S, Patel D, Funahashi T, Giannoni F, Teng BB, Davidson NO, Scott J J BIOL CHEM 1993 268 28 20709-20712
31. 684452 Structure of apolipoprotein B-100 of human low density lipoproteins. Yang CY, Gu ZW, Wang SA, Kim TW, Chen SH, Pownall HJ, Sharp PM, Liu SW, Li WH, Gotto AM Jr ARTERIOSCLEROSIS 1989 9 1 96-108
32. 684464 Structure of apolipoprotein B-100 in low density lipoproteins. Segrest JP, Jones MK, De Loof H, Dashti N J LIPID RES 2001 42 9 1346-1367
33. 684469 Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirty-person/ten-country panel. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD et al J INTERN MED 2006 259 3 247-258
34. 684473 The N-terminal 1000 residues of apolipoprotein B associate with microsomal triglyceride transfer protein to create a lipid transfer pocket required for lipoprotein assembly. Dashti N, Gandhi M, Liu X, Lin X, Segrest JP BIOCHEMISTRY 2002 41 22 6978-6987
35. 684482 Monogenic hypercholesterolemia: New insights in pathogenesis and treatment. Rader DJ, Cohen J, Hobbs HH J CLIN INVEST 2003 111 12 1795-1803
36. 684488 Abetalipoproteinemia is caused by defects of the gene encoding the 97 kDa subunit of a microsomal triglyceride transfer protein. Shoulders CC, Brett DJ, Bayliss JD, Narcisi TM, Jarmuz A, Grantham TT, Leoni PR, Bhattacharya S, Pease RJ, Cullen PM, Levi S et al HUM MOL GENET 1993 2 12 2109-2116
37. 684489 Antisense technologies. Improvement through novel chemical modifications. Kurreck J BIOCHEMISTRY 2003 270 8 1628-1644
38. 684928 Antisense oligonucleotides as therapeutics for hyperlipidaemias. Crooke RM EXPERT OPIN BIOL THER 2005 5 7 907-917
39. 684937 In vivo distribution and metabolism of a phosphorothloate oligonucleotide within rat liver after intravenous administration. Graham MJ, Crooke ST, Monteith DK, Cooper SR, Lemonidis KM, Stecker KK, Martin MJ, Crooke RM J PHARMACOL EXP THER 1998 286 1 447-458
40. 684939 Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. Graham MJ, Crooke ST, Lemonidis KM, Gaus HJ, Templin MV, Crooke RM BIOCHEM PHARMACOL 2001 62 3 297-306
41. 684942 Pharmacokinetics and pharmacodynamics of an antisense, phosphorothloate oligonucleotide targeting Fas mRNA in mice. Yu RZ, Zhang H, Geary RS, Graham M, Masarjian L, Lemonidis K, Crooke R, Dean NM, Levin AA J PHARMACOL EXP THER 2001 296 2 388-395
42. 684944 Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. Geary RS, Watanabe TA, Truong L, Freier S, Lesnik EA, Sioufi NB, Sasmor H, Manoharan M, Levin AA J PHARMACOL EXP THER 2001 296 3 890-897
43. 685131 A human apolipoprotein B antisense inhibitor reduces aortic sinus plaque volume in LDL receptor deficient, human apolipoprotein B-100 transgenic mice. Lemonidis KM, Whipple CP, Graham MJ, Subramaniam A, York-Defalco C, Hung G, Crooke RM ARTERIOSCLER THROMB VASC BIOL 2006 26 Abs 2
44. 685134 A human apolipoprotein B antisense inhibitor reduces aortic sinus plaque volume in LDL receptor deficient mice expressing a human apoB-100 transgene. Chuang E, Lemondis KM, Whipple C, Graham MJ, York-Defalco C, Hung G, Crooke RM ATHEROSCLER SUPPL 2006 7 Abs Th-W49:5
45. 685136 Anti-sense-mediated suppression of hepatic apoB-100 expression produces global changes in cholesterol and fatty acid biosynthetic genes in high-fat-fed mice. Graham MJ, Lemonidis KM, Whipple C, Perera R, Koo S, Subramaniam A, Crooke RM ARTERIOSCLER THROMB VASC BIOL 2004 24 Abs P321
46. 685137 Suppression of apoB by antisense oligonucleotides produces concomitant down stream reductions in lipogenic genes of mice and nonhuman primates. Graham MJ, Kim T, Lemonidis KM, Subramaniam A, Crooke RM CIRC RES 2005 97 11 Abs 5010
47. 685138 Lack of pharmacokinetic interactions of an antisense oligonucleotide, targeting human apoB, when co-administered with simvastatin & ezetimide, in man. Geary R, Yu R, Bradley J, Chuang E, Wedel M, Vanvliet A ATHEROSCLER SUPPL 2006 7 Abs Th-P1 6:258
48. 685140 Significant reduction of small dense LDL-cholesterol concentrations in healthy volunteers by antisense inhibition of apolipoprotein B. Kastelein JJP, Wedel MK, Baker B, Su J, Bradley J, Chuang E ATHEROSCLER SUPPL 2006 7 Abs Th-W49:6
49. 685142 Effect of dose and dose schedule on the efficacy and safety of an antisense inhibitor of apoB in volunteers with mild hypercholesterolemia. Kastelein JJP, Bradley J, Chuang E, Wedel MW, Su J, Geary R A THEROSCLER SUPPL 2006 7 Abs Th-P1 6:268
50. 689020 Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Wierzbicki AS, Doherty E, Lumb PJ, Chik G, Crook MA CURR MED RES OPIN 2005 21 3 333-338
51. 689046 Therapeutic potential of RNA interference. Stevenson M N ENGL J MED 2004 361 17 1772-1777
52. 889052 Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, Marion P, Salazar F, Kay MA NATURE 2006 441 7092 537-541
53. 689054 RNA interference as potential therapy - not so fast. Marsden PA N ENGL J MED 2006 356 9 953-954